CEDAR KNOLLS, N.J., April 16 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) announced today that additional
preclinical in vivo studies using dogs further demonstrate that its
proprietary eligen(R) technology enhances the absorption of oral B12. These
data confirm in a second species Emisphere's earlier-reported proof of
concept studies conducted in rats.
"These additional animal studies are an important milestone in our
plans to commercialize our eligen(R) technology," said Michael V. Novinski,
President and Chief Executive Officer of Emisphere. "Developing a B12
formulation with greater bioavailability will alleviate a significant unmet
medical need."
There are currently some five million people in the United States
receiving 40 million B12 injections annually to treat a variety of
debilitating medical conditions; at least an additional five million people
are consuming over 600 million tablets of B12 of various strengths
annually.
ABOUT EMISPHERE TECHNOLOGIES, INC.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its eligen(R) Technology. These molecules
and compounds could be currently available or are in preclinical or
clinical development. Such molecules or compounds usually cannot be
delivered by the oral route of administration or the benefits of these
compounds are limited due to poor bioavailability, slow on-set of action or
variable absorption. The eligen(R) Technology can be applied to the oral
route of administration as well other delivery pathways, such as buccal,
per rectum, pulmonary, intra-vaginal or transdermal. The web site is:
http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding future performance or
financial results, the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Emisphere's product candidates and the sufficiency of Emisphere's cash and
other capital resources) are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that
actual performance or results could materially differ, that future research
will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or abroad,
the ability of Emisphere and/or its partners to develop, manufacture and
commercialize products using Emisphere's drug delivery technology, or
Emisphere's ability to fund such efforts with or without partners.
Emisphere undertakes no obligation to update any of these statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly any
forward-looking statements should be read in conjunction with the
additional risks and uncertainties detailed in Emisphere's filings with the
Securities and Exchange Commission, including those factors discussed under
the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K for
the fiscal year ended December 31, 2007, filed on March 17, 2008, and our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed
on May 7, 2007 (file no. 000-17758), for the quarter ended June 30, 2007,
filed on August 7, 2007 (file No. 000-17758), and for the quarter ended
September 30, 2007, filed on November 6, 2007 (000-17758).
| |
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com/
CONTACT:
Bob Madison, Senior Director Corporate
Communications, +1-973-532-8001, or Adam Friedman, Adam Friedman
Associates, +1-212-981-2529, extension 18
| |
|
